Pharsight

Hepzato patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11633528 DELCATH SYSTEMS INC Apparatus for removing chemotherapy compounds from blood
Nov, 2032

(8 years from now)

US10369264 DELCATH SYSTEMS INC Apparatus for removing chemotherapy compounds from blood
Nov, 2032

(8 years from now)

US10098997 DELCATH SYSTEMS INC Apparatus for removing chemotherapy compounds from blood
Nov, 2032

(8 years from now)

US11241522 DELCATH SYSTEMS INC Apparatus for removing chemotherapy compounds from blood
Nov, 2032

(8 years from now)

US10569004 DELCATH SYSTEMS INC Apparatus for removing chemotherapy compounds from blood
Nov, 2032

(8 years from now)

US11833286 DELCATH SYSTEMS INC Filter and frame apparatus and method of use
Dec, 2032

(8 years from now)

US11083831 DELCATH SYSTEMS INC Filter and frame apparatus and method of use
Dec, 2032

(8 years from now)

US10195334 DELCATH SYSTEMS INC Filter and frame apparatus and method of use
Jan, 2033

(8 years from now)

US9314561 DELCATH SYSTEMS INC Filter and frame apparatus and method of use
Feb, 2034

(9 years from now)

US9707331 DELCATH SYSTEMS INC Apparatus for removing chemotherapy compounds from blood
Sep, 2034

(10 years from now)

Hepzato is owned by Delcath Systems Inc.

Hepzato contains Melphalan Hydrochloride.

Hepzato has a total of 10 drug patents out of which 0 drug patents have expired.

Hepzato was authorised for market use on 14 August, 2023.

Hepzato is available in powder;intra-arterial dosage forms.

Hepzato can be used as a method of treating a patient with uveal melanoma with unresectable hepatic metastases, a percutaneous hepatic perfusion procedure for treating a patient with uveal melanoma with unresectable hepatic metastases.

The generics of Hepzato are possible to be released after 17 September, 2034.

Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Aug 14, 2026
Orphan Drug Exclusivity(ODE-438) Aug 14, 2030

Drugs and Companies using MELPHALAN HYDROCHLORIDE ingredient

Market Authorisation Date: 14 August, 2023

Treatment: A percutaneous hepatic perfusion procedure for treating a patient with uveal melanoma with unresectable hepatic metastases; A method of treating a patient with uveal melanoma with unresectable hepatic...

Dosage: POWDER;INTRA-ARTERIAL

More Information on Dosage

HEPZATO family patents

Family Patents